Related Experiment Video
Updated: Sep 21, 2025
07:23
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
6.3K
Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
Corrado De Marco1,2, Thierry Charron1,2, Guy Rousseau1,3
1CIUSSS du Nord-de-l'Île-de-Montréal, Hôpital du Sacré-Coeur, Department of Medicine, QC, Montréal, Canada.
Frontiers in Pharmacology
|June 1, 2022
Summary
Adenosine may improve outcomes after acute myocardial infarction by reducing reperfusion injury. Optimizing its administration (dose, timing, route, site) is key to maximizing benefits for heart attack patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) treatment relies on reperfusion.
- Reperfusion injury negatively impacts cardiac recovery.
- Adenosine targets upstream pathophysiological processes of reperfusion injury.
Purpose of the Study:
- To evaluate adenosine's efficacy in AMI.
- To analyze how administration variables influence adenosine's benefits.
Main Methods:
- Review of existing clinical evidence on adenosine in AMI.
- Analysis of study methodologies, focusing on dose, route, timing, and site of administration.
Main Results:
- Mixed clinical outcomes reported for adenosine in AMI.
- Variability in study designs contributes to heterogeneous evidence.
- Specific administration parameters are critical for adenosine efficacy.
Conclusions:
- Adenosine shows clear benefits in treating AMI.
- Its role in AMI management should be reconsidered.
- Optimizing administration protocols is essential for clinical success.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
90
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
90
01:28Acute Coronary Syndrome IV: Interprofessional Care
37
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
37
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
920
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
920
01:30Acute Coronary Syndrome I: Introduction
90
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
90
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
57
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
57
01:16Antianginal Drugs: Nitrates and β-Blockers
775
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
775